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ABSTRACT. North bicyclo methanocarba thymidine (TN) nucleosides were substituted into siRNAs to 
investigate the effect of bicyclo[3.1.0]hexane 2’-deoxy-pseudosugars on RNA interference activity. Here 
we provide evidence that these modified siRNAs are compatible with the intracellular RNAi machinery. 
We studied the effect of the TN modification in a screen involving residue-specific changes in an siRNA 
targeting Renilla luciferase and we applied the most effective pattern of modification to the knockdown 
of murine tumor necrosis factor (TNF-). We also showed that incorporation of TN units into siRNA 
duplexes increased thermal stability, substantially enhanced serum stability and decreased innate 
immunostimulation. Comparative RNAi studies involving the TN substitution and locked nucleic acids 
(LNA) showed that the gene silencing activity of TN -modified siRNAs was comparable to that obtained 
with the LNA modification. An advantage of the North 2’-deoxy-methanocarba modification is that it may 
be further explored in the future by changing the 2’-position. The results from these studies suggest that 
this modification may be valuable for developing siRNAs for therapeutic applications. 
 
Introduction 
RNA interference has become one of the most important new tools for biological research in the past 
decade.[1] This methodology is widely used for knocking down (i.e. regulating) expression of specific 
genes in cell culture and can be carried out conveniently by using synthetic 21-23 nt double stranded 
RNAs, which are known as short interfering RNAs or siRNAs.[2] These oligoribonucleotides are formed 
by a sense and an antisense (or guide) strand, which is complementary in sequence to a fragment of 
the target mRNA. The RNAi process is initiated with the recognition of the siRNA duplex by the RNA-
induced silencing complex (RISC),[3] a protein located in the cytoplasm. After siRNA binding, RISC uses 
the antisense strand as a template to find the target mRNA[4] and induces endonucleolytic cleavage of 
the target mRNA,[5] preventing its translation into protein. 
Despite the significance of RNAi both as a biological tool and as a potential therapeutic strategy, the 
utility of siRNAs in vivo faces some key hurdles including delivery, biostability,[6] and low sequence 
specificity that results in undesired off-target effects.[7] Moreover, cellular receptors such as toll-like 
receptors can bind to siRNAs and trigger innate immune responses, resulting in cytokine production.[8] 
To address these limitations and to further understand the mechanism of silencing, several research 
groups have been actively studying siRNAs with various chemical modifications,[9] specially on the 
sugar moiety.[10]  
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One widely used class of alteration that has been explored involves restriction of the conformation of 
the furanose system of the nucleotide building blocks of siRNAs in the North hemisphere of the 
pseudorotational cycle,[11] which is likely promising for the development of a nucleic acid analogue with 
high binding affinity to its RNA complement. Among this class of modification, incorporation of 
appropriate electronegative substituents at the 2' position of the sugar ring[12] like 2'-fluoro[10a,10b] and 2'-
O-methyl substitutions in the ribo configuration,[10a-10c] has been found to increase stability of siRNAs to 
degradation by nucleases and to improve thermal stability, as measured by Tm values. Moreover, 
Aigner et al. recently described siRNAs containing 2’-azido substitutions.[10d] Interestingly, they found 
that this modification is well accepted by the RNAi machinery. 
 Another 2'-sugar modification that has been investigated involves addition of a methylene bridge 
between the 2' oxygen and the 4' carbon of the furanose ring.[13] The resulting nucleotides and 
oligonucleotides containing these monomers are called “locked nucleic acids” (LNA)[14] since the 
conformation of their bicyclic furanose ring is locked in the North hemisphere of the pseudorational 
cycle (3'-endo conformation),[11] thus retaining conformationally RNA-like A-type helical characteristics 
for effective gene silencing. Several studies have demonstrated that the LNA modification increases the 
thermodynamic and serum stability of siRNA duplexes to a great extent[15,10e,10i] and that single RNA to 
LNA exchanges at base paired positions in the antisense strand are tolerated in most of the positions 
that have been investigated.[10e]  
 Other conformationally restricted nucleoside analogues have been synthesized and incorporated into 
oligonucleotide strands.[16] For example, bicyclodeoxynucleosides,[16a,16b] which contain an ethylene 
bridge between the 3’ and the 5’ carbons of the furanose ring, and tricyclodeoxynucleosides,[16c-g] with 
an additional cyclopropane ring fused to the ethylene bridge. The resulting oligonucleotides containing 
these units are called bc-DNA and tc-DNA, respectively. In particular, tc-DNA modifications have been 
found to favor an A-form double helix.[16e] In recent studies, Ittig et al. have found that incorporation of 
tc-DNA units in various positions of siRNAs can improve RNAi activity and serum stability.[16g]  
Another candidate for introducing new features into siRNAs without perturbing the overall A-form 
helical structure required for activity is the North-locked form of 2'-deoxynucleoside analogues based on 
a carbocyclic bicyclo[3.1.0]hexane system (2'-deoxy-methanocarba (MC) nucleosides).[17] The design 
and synthesis of 2'-deoxy-MC nucleosides have been summarized.[18] Moreover, it has been found that 
incorporation of North 2’-deoxy-MC thymidine (TN) units into oligodeoxynucleotide strands increases the 
thermal stability of the corresponding ODN/RNA heteroduplexes.[17b,18b] But despite the efficient 
hybridization of North 2'-deoxy-MC nucleoside analogues, these derivatives have never been 
incorporated into RNA strands and therefore, they have never been tested for their effects on the RNAi 
process. In this work we explore the replacement of the natural sugar ring of siRNAs by the North 
conformational restricted carbocyclic bicyclo[3.1.0]hexane system. In particular, we focus on siRNAs 
modified with the North 2'-deoxy-MC thymidine derivative (TN, Figure 1). Herein we report studies which 
directly compare the gene silencing efficiency of TN-modified siRNAs and native siRNA molecules. In 
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particular, we focus mainly on the modification of the guide strand, which has been reported to be more 
sensitive to chemical modification compared with the sense strand.[10a,19] Because of the importance of 
the guide strand on the RNAi process, modification of this strand can provide useful information on the 
RNAi mechanism and on guide siRNA-RISC interactions. However, most of the focus to date has been 
on modifying the sense strand, which tolerates better chemical modification.[10e] To carry out such 
study, we first evaluated the effect of the TN modification on the ability of siRNAs to inhibit the 
expression of a luciferase gene. In addition, we studied the use of this modification for inhibiting the 
expression of the murine tumor necrosis factor (TNF-a) gene. This research is an ongoing project 
aimed to the search of anti-inflammatory siRNAs to treat Crohn’s disease. A critical issue in the design 
of anti-inflammatory siRNAs is the inhibition of innate immune response. In this work, we also 
demonstrate that RNA to TN replacement decreases immunostimulation. 
Moreover, we evaluated the effect of these substitutions on the thermal and serum stability of the 
corresponding siRNA duplexes. We also compared the gene silencing activity of two TN-modified 
siRNAs and their LNA thymine (TL)-modified versions. Our results suggest that the RNAi activity of our 
TN-modified siRNAs was comparable to that of their TL-modified versions. These properties and the fact 
that the 2'-deoxy-methanocarba nucleosides have an open 2'-position allows the exploration of 
chemical diversity at such site to give new, North MC-modified siRNAs with yet unexplored therapeutic 
applications. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Chemical structures of the conformationally restricted thymidine analogues used in this study 
Results and Discussion 
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Design and synthesis of modified guide and sense strands targeting the Renilla luciferase gene 
We first designed a large number of 21-mer TN-modified siRNA duplexes targeting the A-rich site 501–
519 of Renilla luciferase mRNA[9d,9e,9g] (Figure 2B). We chose a luciferase model system because it 
allowed rapid determination of RNAi activity. This sequence allowed us to make a large number of 
substitutions into the guide strand by using the TN monomer (replacement of natural U by TN). The 
North 2'-deoxy-MC thymidine monomer was synthesized according to the literature.[17b] This 
modification could be introduced into RNA without substantial alteration of standard synthesis protocols 
(see Materials and Methods). 
We synthesized siRNAs containing no modifications (1), a single TN substitution at position 1 (2), 2 
(4), 10 (5), 11 (6), and 20 (7) of the guide strand, one modification at both ends of the guide strand (8), 
three modifications on the 5' half (9) and three modifications on the 3' half (10), six TN substitutions at 
spaced out positions along the guide strand (11) and eleven TN substitutions (12). We also modified the 
3' dinucleotide overhangs to give siRNAs 13 (modification of the guide strand), 14 (modification of the 
sense strand), and 15 (modification of both strands). Moreover, we prepared siRNA 16, which contains 
a single TN substitution at position 2 of the sense strand, and the 5'-phosphorylated version of siRNA 2 
(3). Finally, we synthesized LNA-modified versions of siRNAs 7 and 11 (17 and 18), in order to 
compare their RNAi activity. 
 
Thermal stability of North methanocarba thymidine-modified siRNA duplexes 
After RNA synthesis we measured the effects of these substitutions on thermal stability of the siRNA 
duplexes (Figure 2B). Thermal stability is an important variable to evaluate when considering the value 
of chemical modifications to siRNA. For example, it may play a substantial role in the stability of the 
duplex to degradation by nucleases, as formation of thermodynamically stable duplexes may prevent 
the degradation of the constituent RNA strands by single-stranded nucleases. On the other hand, the 
level of siRNA duplex stability is also a critical parameter for siRNA activity.[10a] However, it has been 
suggested that there is a limit to how stable the duplex can be. In the work by Chiu et al. it was reported 
that an excessive thermal duplex stabilization can interfere with siRNA unwinding.[10a] 
Figure 2. (A) Plot of gene-specific RNAi activity for TN-modified siRNAs targeting the Renilla luciferase mRNA in 
SH-SY5Y cells. Varied amounts of siRNA were added as shown. (B) Sequences of unmodified, TN-modified and 
TL-modified siRNAs targeting the Renilla luciferase mRNA and Tm data. Top strand depicts the sense strand in the 
5’–3’ direction (same as the target sequence). Bottom strand depicts the antisense strand in the 3’–5’ direction 
(complementary to the target). TN: North methanocarba thymidine monomer, TL: LNA thymidine monomer. Scr: 
scrambled sequence. (C) Plot comparing the gene silencing activity of North methanocarba thymidine-modified 
siRNAs 7 and 11 and the LNA-modified siRNAs 17 and 18 targeting the Renilla luciferase mRNA in SH-SY5Y 
cells. Untreated cells: cells treated with plasmids alone. Bars indicate standard deviation. 
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A)  
 
 
 
 
 
 
Compared to the unmodified RNA sequence (1), all substituted oligoribonucleotides containing TN 
substitutions at base-paired positions had greater duplex stability (as evaluated by higher Tm values) 
when hybridized to their RNA complement (see data in Figure 2B). The incorporation of North 2'-deoxy-
MC thymidine residues resulted in an increase of 0.8–2 ºC per modification depending on the position 
of the pseudonucleoside. Such stabilizing effect was found to be additive. This is in agreement with the 
previously reported thermodynamic stability of TN-modified ODN/RNA heteroduplexes.[18a,18c] The rank 
order of duplex Tm was: eleven TN (12) > six TN (11) > three TN on the 5' half (9) > three TN on the 3' half 
(10) ~ one TN at position 10 of the guide strand (5) > one TN at position 11 (6) > one TN at position 2 of 
the guide strand (4 and 8) ~ one TN at position 2 of the sense strand (16) and one TN at position 1 of the 
guide strand (2). 
A singly modified LNA-siRNA duplex was as stable as the corresponding TN-siRNA duplex (17 and 7) 
while an LNA-siRNA with multiple substitutions was more stable than the corresponding TN-siRNA 
siRNA                       Sequence 
 
11 
 
TTAAAAAGAGGAAGAAGUCUA-5'  
 5'-UTNUTNUCTNCCUUCUTNCAGATNTNT 
 
12 
 
TTAAAAAGAGGAAGAAGUCUA-5'  
5'UTNTNTNTNCTNCCTNTNCTNTNCAGATNTNT 
 
13 
 
TTAAAAAGAGGAAGAAGUCUA-5'  
 5'-UUUUUCUCCUUCUUCAGAUTNTN 
 
14 
 
TNTNAAAAAGAGGAAGAAGUCUA-5'  
 5'-UUUUUCUCCUUCUUCAGAUTT 
 
15 
 
TNTNAAAAAGAGGAAGAAGUCUA-5'  
 5'-UUUUUCUCCUUCUUCAGAUTNTN 
 
16 
 
TTAAAAAGAGGAAGAAGUCTNA-5'  
 5'UUUUUCUCCUUCUUCAGAUTT 
 
17 
 
TTAAAAAGAGGAAGAAGUCUA-5'  
 5'-UUUUUCUCCUUCUUCAGAUTLT 
 
18 
 
TTAAAAAGAGGAAGAAGUCUA-5'  
 5'-UTLUTLUCTLCCUUCUTLCAGATLTLT 
scr TTAGGAAAGAAAGAAAGCUAU-5'  
5'-UCCUUUCUUUCUUUCGAUATT 
siRNA                       Sequence Tm 
(ºC) 
   
1 
 
TTAAAAAGAGGAAGAAGUCUA-5'  
 5'-UUUUUCUCCUUCUUCAGAUTT 
 
67.8 
 
2 
 
TTAAAAAGAGGAAGAAGUCUA-5'  
 5'-TNUUUUCUCCUUCUUCAGAUTT 
 
68.6 
 
3 
 
TTAAAAAGAGGAAGAAGUCUA-5'  
 5'-pTNUUUUCUCCUUCUUCAGAUTT 
 
_ 
 
4 
 
TTAAAAAGAGGAAGAAGUCUA-5'  
 5'-UTNUUUCUCCUUCUUCAGAUTT 
 
68.9 
 
5 
 
TTAAAAAGAGGAAGAAGUCUA-5'  
 5'-UUUUUCUCCTNUCUUCAGAUTT 
 
69.7 
 
6 
 
TTAAAAAGAGGAAGAAGUCUA-5'  
 5'-UUUUUCUCCUTNCUUCAGAUTT 
 
69.1 
 
7 
 
TTAAAAAGAGGAAGAAGUCUA-5'  
 5'-UUUUUCUCCUUCUUCAGAUTNT 
 
67.8 
 
8 
 
TTAAAAAGAGGAAGAAGUCUA-5'  
 5'-UTNUUUCUCCUUCUUCAGAUTNT 
 
68.7 
 
9 
 
TTAAAAAGAGGAAGAAGUCUA-5'  
 5'-UTNUTNUCTNCCUUCUUCAGAUTT 
 
71.4 
 
10 
 
TTAAAAAGAGGAAGAAGUCUA-5'  
 5'-UUUUUCUCCUUCUTNCAGATNTNT 
 
69.7 
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duplex [Tm = 79.7 ºC for siRNA 18 (containing six TL residues) versus Tm = 72.8 ºC for its TN-modified 
version (11)]. 
Figure 2. (C) Plot comparing the gene silencing activity of North methanocarba thymidine-modified siRNAs 7 and 
11 and the LNA-modified siRNAs 17 and 18 targeting the Renilla luciferase mRNA in SH-SY5Y cells. Untreated 
cells: cells treated with plasmids alone. Bars indicate standard deviation 
 
 
CD spectra of TN-modified siRNA duplexes 
We determined CD spectra of selected siRNAs [siRNAs containing no modifications (1), one TN 
(5), two TN (8), three TN (9), six TN (11) and eleven TN (12)]. The spectra clearly indicate that the overall 
conformation of a typical A-form double helical geometry is retained in the TN-modified siRNAs (see the 
Supplementary Figure S5). 
RNAi activity of TN-modified siRNAs targeting Renilla luciferase gene 
RNAi studies in SH-SY5Y cells with siRNAs containing each of the eleven TN-modified guide 
strands (2-12), siRNAs modified at the 3' dinucleotide overhangs (13-15), siRNA 16 (containing a single 
TN substitution into the sense strand), as well as with the unmodified (wild type) RNA (1), were 
performed. Experiments were carried out in triplicate. The cells were first transfected with dual reporter 
plasmids that express Renilla luciferase (the target) and non-targeted firefly luciferase as an internal 
control. The effects of the different RNAs on luciferase expression were evaluated after dosing with 
0.21-210 ng (0.03-26 nM) of double stranded RNA in the cell media, and measuring luminiscence 
responses after 22 h. The results, showing Renilla luciferase activity normalized to firefly luciferase, are 
represented in Figure 2A. 
In a first series of experiments, we compared the positional effect of the TN modification on RNAi by 
making single RNA to TN exchanges at relevant base-paired positions in the guide strand (siRNAs 2-7, 
Figure 2B). It has been suggested that the position 1 of the guide strand plays a critical role for siRNA 
function and is more sensitive to chemical modification. Compared to the unmodified or wild type siRNA 
(1), incorporation of one TN residue on the 5' end of the guide strand (position 1, siRNA 2) caused a 
significant decrease in luciferase activity at the highest siRNA concentration (26 nM). It is known that a 
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5' phosphate is crucial for siRNA function; therefore, to exclude the possibility that the 5'-modified 
siRNA 2 was poorly recognized by cellular kinases resulting in loss activity due to the lack of a 5'-
phosphate, we synthesized the 5'-phosphorylated version of siRNA 2 (3). However, this procedure did 
not recover any of the lost effect (Figure 2A). In contrast to what was observed for compound 2, 
incorporation of a TN residue at position 2 of the guide strand (4) gave rise to a gene silencing activity 
comparable to that of wild type siRNA (1).  
Next, we examined the effect of incorporating a TN residue at position 10 of the guide strand (5). It is 
known that this position plays an important role for the siRNA function too since mRNA cleavage occurs 
between position 10 and 11 of the guide strand counting from the 5' end. When we incorporated a TN 
residue at position 10 of the guide strand we observed a decrease in gene silencing activity. However, 
the resulting modified siRNA (5) retained significant activity (at the lowest siRNA concentration (0.03 
nM), Renilla luciferase expression was ~83% for 5 and ~68% for wild type siRNA (1)). In contrast, RNA 
to TN replacement at position 11 did not disrupt RNAi activity. siRNA 6 displayed gene silencing activity 
comparable to that observed for wild type siRNA (1). Moreover, guide siRNA having one TN substitution 
at position 20 (7) displayed slightly better activity than that observed for unmodified siRNA 1. The most 
significant differences were observed when very low concentrations (0.03 nM) of siRNAs were 
employed (significant differences were assessed by ANOVA to compare three or more groups followed 
by Bonferroni test (see data in Supplementary Figure S1A)). At the lowest siRNA concentration (0.03 
nM), 44% ± 3 gene knockdown for 7 versus 32% ± 4 for 1 (p < 0.05). It is noteworthy that, compared to 
the 5'-modified siRNA 4 (TN at position 2), this 3'-modified siRNA (7) displayed slightly better activity.  
Since the above described experiments suggest that, with a few exceptions, siRNAs containing a 
single substitution on the guide strand could effectively mediate RNAi activity to levels comparable to 
the wild type siRNA, it was of interest to study the effect of multiple substitutions on RNAi activity. We 
first incorporated one TN substitution at both ends of the guide strand (positions 2 and 20, siRNA 8). 
The resulting disubstituted siRNA displayed RNAi activity similar to that observed for the wild type 
siRNA (1). On the other hand, incorporation of three TN residues on the 5' half (positions 2, 4, and 7, 
siRNA 9) caused a slight loss of the interference activity. Although the resulting modified siRNA (9) was 
significantly active, it showed decreased activity as compared with the siRNA containing two TN 
residues (8). However, incorporation of three substitutions on the 3' half (positions 14, 19 and 20, 
siRNA 10) recovered all the lost effect. siRNA 10 displayed gene silencing activity slightly better than 
that of siRNA 9 and comparable to that of the wild type siRNA (1) (Bonferroni test, p < 0.05; see the 
Supplementary Figure S1B) (at an siRNA concentration of 0.03 nM, Renilla luciferase gene silencing 
was 25% ± 7 for 8, 20% ± 8 for 9, 28% ± 3 for 10 and 32 % ± 4 for 1). These and the above-described 
effects (for siRNAs 4 and 7, containing a single TN substitution at the 5'-end and at the 3'- end, 
respectively) support the idea that the sequence structure within the 5' region of the antisense strand is 
more sensitive to chemical modification than in the 3' region.[10a] This is also consistent with previous 
observations that incorporation of 2'-FU, 2'-FC, dAs and dGs residues predominantly on the 5' half of a 
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siRNA caused a significant loss in gene silencing activity, whereas siRNAs containing 2'-FU, 2'-FC, dAs 
and dGs modifications predominantly on the 3' half retained a significant level of gene silencing.[10a] 
Having demonstrated that three TN substitutions can be tolerated by the RNAi machinery, we studied 
the effect of a higher number of substitutions in the guide strand. For siRNA containing six TN 
substitutions at spaced-out positions along the guide strand (11), gene silencing activity was 
significantly less efficient than that observed for wild type, disubstituted and tribustituted siRNAs (1, 8, 9 
and 10, respectively). However, despite this loss in activity, siRNA 11 retained significant inhibitory 
effect at the highest dose of 26 nM (~12% Renilla luciferase expression for 11 versus ~4% for 1). 
In order to ensure that the loss in activity observed for double stranded 11 was due to the presence 
of excessive modifications we incorporated eleven TN residues in the antisense strand (12). As 
expected, fully substituted siRNA 12 disrupted Renilla luciferase-specific RNAi activity. Incorporation of 
eleven TN substitutions within the guide strand caused loss of most of the interference activity even at 
the highest siRNA concentration (26 nM).  
The above described results indicate that in general, incorporation of one to three nucleotides in the 
guide strand is well tolerated by the RNAi machinery. However, the North 2'-deoxy-MC modification is 
not tolerated when oligoribonucletides contain more than six substitutions. On the other hand, 
introduction of TN modifications in the 3' overhangs in the antisense (13), the sense (14) or both strands 
(15) led to similar activity (Figure 2A and Figure S1C). 
In the report by Elmén et al. it was suggested that introduction of a single LNA modification at the 5'-
terminal end (position 1) of the sense strand allows preferential incorporation of the guide strand into 
RISC, thereby improving gene silencing efficiency and reducing the sense strand-specific off- targeting 
activity.[10e] Although North 2'-deoxy-MC nucleosides and LNAs are different in structure, both of them 
possess conformationally restricted ring systems and are bridged bicyclic compounds. In order to study 
the effect of the modification of the sense strand with a TN residue we chose the neighboring position 
(position 2) (siRNA 16, Figure 2B). Interestingly, the resulting siRNA (16) displayed slightly better 
activity than that of the unmodified siRNA 1 (Figure 2A and Supplementary Figure S1D; Bonferroni test, 
p < 0.05). At an siRNA concentration of 0.03 nM, 44% ± 1 of gene knockdown was observed for 16 
versus 32% ± 4 gene knockdown for 1. Gene silencing was comparable to that observed for the 3'-
modified siRNA 7, which contains a single TN substitution at position 20 of the guide strand.   
To ensure the specificity of the above-described effects, sequence-scrambled siRNAs (as negative 
controls) were used. Cells co-transfected with scrambled versions of the unmodified siRNA 1 (scr) and 
scrambled versions of two of the more active chemically modified siRNAs (10 and 16) displayed Renilla 
luciferase activity similar to those of cells transfected with plasmids alone (see data in Figure 2A and in 
the Supplementary Figures S3 and S4). These results indicate that the siRNAs used in this study 
specifically induce inhibition of expression of the target gene. 
Finally, we compared the RNAi activity of one of the most active and one of the less active TN-
modified siRNAs (7 and 11, respectively) versus their LNA-modified versions (siRNA 17, which contains 
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a single LNA thymine substitution (TL) at position 20 of the guide strand, and siRNA 18, which contains 
six TL residues at spaced out position along the guide strand). The results are represented in Figure 
2C. Interestingly, SH-SY5Y cells co-transfected with TN-modified siRNAs 7 and 11, and plasmids 
encoding Renilla and firefly luciferase genes showed gene silencing activity comparable to that of cells 
transfected with their LNA-modified versions (siRNAs 17 and 18, respectively) and the luciferase 
plasmids.  
RNAi activity of TN-modified siRNAs targeting murineTNF-a 
TNF-a factor (a pro-inflammatory cytokine) is a major mediator of apoptosis, inflammation and 
immunity. Furthermore, TNF-a has been implicated in the pathogenesis of many human diseases; for 
example, Crohn’s disease, which is an inflammatory disorder. Thus, efficient knockdown of this factor 
could have beneficial consequences on human health. Our group has been interested in the 
development of anti-inflammatory siRNAs to treat Crohn’s disease. In recent studies we have 
developed new delivery systems which involved conjugation of lipids and peptides to the ends of an 
siRNA targeting murine TNF-a mRNA.[20] On the other hand, this work is aimed at increasing the 
binding affinity and nuclease stabillty of these siRNAs. For these reasons, the effect of TN-modified 
siRNAs on the inhibition of expression of murine TNF-a gene were examined. 
Two of the most promising modified siRNA designs, corresponding to siRNAs 7 and 16 were 
selected from our previous luciferase gene silencing results and used for targeting murine TNF-a 
mRNA in RAW cells (murine peritoneal macrophages) using a previously reported sequence [20] (see 
the sequence in Figure 3A). We synthesized unmodified siRNA 19 and TN-modified siRNAs 20 and 21 
targeting murine TNF-a (Figure 3A), which contained TN modifications at the same positions as siRNAs 
7 and 16 [one TN substitution at position 20 of the guide strand (20) and one TN substitution at position 
2 of the sense strand (21)]. Moreover, we synthesized two disubstituted siRNAs targeting murine TNF-
a, one of them (22) containing TN modifications at positions 6 and 20 of the guide strand, and the 
second one (23) containing TN modifications at positions 2 and 18 of the sense strand. Levels of TNF-a 
protein after treating the cells with siRNAs (100 nM concentration per well) were analyzed by enzyme-
linked immunoabsorbent assay (ELISA) (Figure 3B). Gene silencing experiments were carried out in 
triplicate and included controls in which cells were treated with a non-targeting, scrambled siRNA (scr), 
which was selected from our luciferase siRNA assays. Disubstituted siRNAs 22 and 23 were the least 
potent of the set but still demonstrated gene silencing activity. On the other hand, monosubstituted 
siRNAs 20 and 21, which contain the TN modification at the same positions as the most active siRNAs 
targeting Renilla luciferase, silenced the expression of murine TNF-a, with activities comparable to the 
unmodified siRNA (19). These results suggest that the most effective patterns of modification that 
emerged from the Renilla luciferase studies (which involved one TN substitution) could be used to target 
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a wide variety of mRNA targets, while two TN substitutions seem to be less tolerated by this 
endogenous gene. 
A) 
 
 
 
 
B) 
 
 
 
 
 
 
 
Figure 3. (A) Sequences of unmodified (19) and TN-modified (20, 21, 22 and 23) siRNAs targeting murine 
TNF-a mRNA. Top strand sepicts the sense strand in the 5’-3’direction (complementary to the target). (B) Plot 
showing the amount of TNF-a produced after 30 h of transfection of 100 nM unmodifed and TN-modified siRNAs 
targeting the murine TNF-a mRNA in RAW cells (murine peritoneal macrophages). Bars indicate standard 
deviation 
 
siRNA Sequence 
 
19 
 
TTCUCCGACUCUGUAUCCGUG-5'  
5'-GAGGCUGAGACAUAGGCACTT 
 
20 
 
TTCUCCGACUCUGUAUCCGUG-5'  
5'-GAGGCUGAGACAUAGGCACTNT 
 
21 
 
TTCUCCGACUCUGUAUCCGTNG-5'  
5'-GAGGCUGAGACAUAGGCACTT 
 
22 
 
TTCUCCGACUCUGUAUCCGUG-5'  
5'-GAGGCTNGAGACAUAGGCACTNT 
 
23 
 
TTCTNCCGACUCUGUAUCCGTNG-5'  
5'-GAGGCUGAGACAUAGGCACTT 
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Immunostimulation 
It is known that siRNAs can induce strong interferon-a (IFN-a) responses in human peripheral blood 
mononuclear cells (PBMC).[8] In order to investigate if TN-modified siRNAs can reduce the undesired 
immunostimulatory activity in PBMCs, we treated human PBMCs with unmodified siRNA 19 (which is 
known to have immunostimulatory activity in human PBMCs) and with the TN-modified siRNAs that had 
been used for targeting TNF-a in murine peritoneal macrophages (20, 21, 22 and 23) at a 10 nM siRNA 
concentration by using DOTAP as the delivery system. Immunostimulated PBMC produce an array of 
cytokines including hTNF-a, IFN-a and IL-6 after siRNA transfection, from which hTNF-a was selected 
and measured 24h after transfection as indicator of immunomodulation in our experiments (Figure 4). It 
is important to mention that murine anti-TNF-a siRNAs 19-23 do not inhibit expression of hTNF-a. 
Treatment of human PBMCs with siRNA 20 resulted in immunostimulation levels comparable to those 
obtained for unmodified siRNA 19. However, incorporation of one TN substitution at position 2 of the 
sense strand (siRNA 21) and two substitutions at positions 6 and 20 of the guide strand (siRNA 22) 
lead to immunostimulation levels significantly lower than those obtained for unmmodified siRNA (19). 
Production of hTNF-a (pg/mL) was 299 ± 18 for 21 and 286 ± 33 for 22, versus 390 ± 35 for 19; 
Bonferroni test, p < 0.05). Moreover, sense-disubstituted siRNA 23 lead to immunostimulation levels 
even lower than those obtained for siRNAs 21 and 22 (217 ± 33 pg/mL hTNF-a for 23 versus 390 ± 35 
pg/mL hTNF-a for 19; p < 0.005).  These results suggest that in siRNA TN replacement along the guide 
or sense strand reduce induction of hTNF-a in PBMCs and that this effect depends on the position and 
the number of TN substitutions.  
 
 
 
 
 
 
 
Figure 4. hTNF-a levels in human PBMC cells 24 h after treatment with unmodified and TN-modified siRNAs (10 
nM) transfected with DOTAP. hTNF-a levels were measured using an enzyme-linked immunoabsorvent assay 
(ELISA kit). hTNF-a levels in response to unmodified siRNA are shown in black and TN-modified siRNAs in grey. 
Serum stability of North 2’-deoxy-MC thymine-modified siRNAs 
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Since the above described experiments showed that most of the TN-modified siRNAs that 
were tested could effectively mediate RNAi to levels comparable to wild type siRNA, and that 
the TN modification can be used to increase the thermal stability of siRNA duplexes, it was of 
interest to study the serum stability of these oligonucleotides. To carry out such studies, 
unmodified or modified double stranded RNAs were incubated in 50% human serum. At 
various time points, siRNAs were extracted, analyzed on a 14% polyacrylamide gel under 
denaturing conditions and visualized by staining. Here we describe the most representative 
examples: unmodified oligoribonucleotide 1 and siRNAs 11, 15 and 16 (Figure 5 and 
Supplementary Figure S2). SiRNA 15 was designed to enhance exonuclease resistance (it 
contains TN modifications at both 3' ends). SiRNA 11, which contains five substitutions at base-
paired positions in the guide strand, was designed to increase the thermal stability of the 
duplex. Finally, siRNA 16 (one TN base-paired substitution in the sense strand) is one of the 
most active oligonucleotides.  
Compared to unmodified siRNA 1, the TN-modified siRNAs displayed higher serum stability. 
As shown in Figure 5 and in Supplementary Figure S2, unmodified siRNA (1) was rapidly 
degraded, with 27%, 4% and 0% of the original siRNA remaining intact through 4, 7 and 9 h, 
respectively. Modification of both 3' dinucleotide ends of the siRNA (siRNA 15) gave rise to an 
increase in the serum stability of the duplex, with 52%, 25% and 20% of the original siRNA 
remaining intact through 4, 7 and 9 h, respectively. Similar results were obtained for siRNAs 
containing a single TN substitutions at position 20 of the guide strand and modifications in the 
3' dinucleotide overhang in either strands of the duplex (siRNAs 7, 13 and 14, respectively) 
(data not shown). On the other hand, double stranded siRNA with one TN residue at position 2 
of the sense strand (16) demonstrated a significant increase in stability over the course of the 
experiment, with 50% of the original siRNA remaining intact through 9 h. Interestingly, siRNA 
containing six TN substitutions (11) displayed strongly enhanced stability, with 84% of the 
siRNA population remaining intact after 9 h. The original siRNA was completely degraded after 
48 h in serum (see the Supplementary Figure S2). Similar results were obtained for siRNA 12, 
which contains eleven TN substitutions in the guide strand (data not shown).  
Thus, we can conclude that the TN modification confers a significant stabilization of siRNAs in 
serum. 
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Figure 5. Serum stability of unmodified and TN-modified siRNAs. The different siRNA were incubated in 50% 
human serum at 37 ºC and withdrawn at indicated time points. Plot of the remaining intact siRNA (%) over 
incubation time. 
 
Conclusion 
In this work we have demonstrated that the North 2'-deoxy-MC substitution is substantially 
compatible with the RNAi machinery. The gene silencing activity of the corresponding modified siRNAs 
depends on the position and the number of the substitutions. We have shown that incorporation of one 
to three substitutions into the guide strand is, in general, well tolerated in a luciferase system. In 
contrast to this, a greater number of substitutions are detrimental to activity, despite the enhanced 
serum and thermal stability of the corresponding modified siRNAs.  
On the other hand, the TN-modified siRNAs that were compared with the LNA thymidine modification 
showed similar activity (siRNAs 7 and 11 versus siRNAs 17 and 18; see data in Figure 2C). Thus, our 
results suggest that the effect on RNAi activity caused by the North 2'-deoxy-MC modification might be 
similar to that observed for the LNA substitution.  
Moreover, the TN modification confers resistance of siRNAs against nucleases and such stabilizing 
effect increases with the number of substitutions. 
Finally, the North 2'-deoxy-MC can also be used in the design of anti-inflammatory siRNAs targeting 
murine TNF-a. In this case, innate immunostimulation effects are clearly reduced by the introduction of 
a few units of this pseudonucleoside. This result is in agreement with the general observation that 
modifications at the carbohydrate moiety may reduce immunostimulation.[21] 
In summary, from this work we can conclude that the effect of the North 2'-deoxy-MC modification on 
RNAi is similar to that of LNA and therefore North 2'-deoxy-MC nucleosides are promising candidates 
for developing new RNA agents for biomedical applications of siRNAs. Moreover, alteration of the 2'-
position of the pseudosugar with different functional groups may offer an avenue for the development of 
new potentially active MC-modified siRNAs with groups that may even reach beyond the 2'-OH.  
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In these studies we have demonstrated for the first time that siRNAs carrying a constrained 
cyclopentane ring embedded in a bicyclo[3.1.0]hexane system can induce the RNAi process. These 
results are in agreement with previous studies reported by Hoshika et al.[22] which suggested that the 
oxygen atom of the ribose moiety was not necessary and that it could be replaced by a sulfur atom. 
This means that replacement of this oxygen by sulfur or a carbon might yield novel modified siRNAs 
with improved properties as long as the North sugar pucker is conserved. 
Experimental Section 
Nucleoside phosphoramidite synthesis: The 5'-O-DMT protected 2'-deoxy-MC thymidine 3'-O-
phosphoramidite was prepared as described. [23] 
 
CPG functionalization: The polymer support was functionalized with North 2'-deoxy-MC thymidine as 
described for natural nucleosides. [24] 
Step I (preparation of 5'-O-DMT-protected North 2'-deoxy-MC thymidine-3'-O-succinate): To a solution 
of 5'-O-DMT-protected North 2'-deoxy-MC thymidine[18a,24] (1 mmol) in dichloromethane (0.2M), succinic 
anhydride (1.3 mmol), diisopropylethylamine (1.4 mmol) and dimethylaminopyridine (0.1 equiv) were 
added. The resulting solution was stirred for 24 h at room temperature and then washed with 1% 
dihydrogen phosphate. The aqueous layer was extracted with CH2Cl2 and the organic layer was dried 
with MgSO4 and evaporated.  
Step II: 2,2'-Dithio-bis-(5-nitropyridine) (0.1 mmol) dissolved in 400 µL of a mixture of acetonitrile-
dichloroethane (1:3) was mixed with a solution of 5'-O-DMT-protected North 2'-deoxy-MC thymidine-3'-
O-succinate (0.1 mmol) and DMAP (0.1 mmol) in acetonitrile (500 µL). The clear solution that was 
obtained was added to a solution of triphenylphosphine (0.1 mmol) in acetonitrile (200 µL) at room 
temperature. The mixture was vortexed for few seconds and then added to a vial containing CPG (500 
Å, 500 mg) and allowed to react 30 min at room temperature. Then, 500 µL of methanol were added 
and the support was recovered on a sintered glass funnel followed by washings with methanol (2 x 5 
mL) and diethyl ether (2 x 5 mL). The support was air dried and then placed under high vacuum. The 
support was subjected to capping following the standard protocol.[25] The North 2'-deoxy-MC thymidine 
loading on the derivatized support was determined by the acid treatment method.[25] 
 
RNA synthesis and purification methods: RNA oligonucleotides were synthesized on the 0.2 µmol 
scale on an Applied Biosystems 394 synthesizer using 2'-O-TBDMS protected phosphoramidites. 
Acetonitrile (synthesis grade) and the 2'-O-TBDMS protected phosphoramidite monomers of A, C, G 
and U were from commercial suppliers. Tetrazole was used as activator. The coupling time was 15 min. 
P (III) to P (V) oxidation was performed with a solution of 10% tert-butyl hydroperoxide in 
acetonitrile/water (96:4) with a 10 min oxidation time. Chemical phosphorylation reagent procured from 
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Link Technologies was used to phosphorylate the 5' end of a modified oligonucleotide. All 
oligonucleotides were synthesized in DMT-on mode. After the solid-phase synthesis, the solid support 
was transferred to a screw-cap glass vial and incubated at 55 ºC for 1 h with 1.5 mL of NH3 solution 
(33%) and 0.5 mL of ethanol. The vial was then cooled on ice and the supernatant was transferred into 
a 2 mL eppendorf tube. The solid support and vial were rinsed with 50% ethanol (2 x 0.25 mL). The 
combined solutions were evaporated to dryness using an evaporating centrifuge. The residue that was 
obtained was dissolved in a total volume of 85 µL of 1M TBAF in THF and rocked at room temperature 
for 12 h. Then, 85 µL of 1M triethylammonium acetate and 330 µL of water were added to the solution. 
The oligonucleotide was desalted on a NAP-5 column using water as the eluent and evaporated to 
dryness. The oligonucleotide was purified by high-performance liquid chromatography (HPLC; DMT-
on). The HPLC conditions were as follows: column: PRP-1 (Hamilton) 250 x 10 mm; solvent A = 5% 
acetonitrile in 100 mM triethylammonium acetate, pH 6.5; solvent B = 70% acetonitrile in 100 mM 
triethylammonium acetate pH 6.5; gradient: 0–30 min, from 15 to 100% in B with UV detection at 260 
nm. The pure fractions were combined and evaporated to dryness. The residue that was obtained was 
treated with 1 mL of 80% AcOH solution and incubated at room temperature for 30 min. The 
deprotected oligonucleotide was desalted on a NAP-10 column using water as the eluent. All 
oligonucleotides were quantified by absorption at 260 nm and confirmed by MALDI mass spectrometry 
(see data in Supplementary Table S1). 
 
UV-monitored thermal denaturation studies: Absorbance versus temperature curves of duplexes 
were measured at 1 µM strand concentration in 15 mM HEPES-KOH (pH 7.4), 1 mM MgCl2 and 50 mM 
KOAc buffer. Experiments were performed in Teflon-stoppered 1 cm path lenght quartz cells on a 
JACSO V-650 spectrophotometer equipped with a thermoprogrammer. The samples were heated to 90 
ºC, allowed to slowly cool to 25 ºC, and then warmed during the denaturation experiments at a rate of 1 
ºC/min to 85 ºC, while monitoring absorbance at 260 nm. The data were analyzed by the denaturation 
curve processing program, MeltWin v. 3.0. Melting temperatures (Tm) were determined by computerfit 
of the first derivative of absorbance with respect to 1/T. 
 
CD measurements 
 
CD spectra were recorded on a Jasco J-810 spectropolarimeter equipped with a Julabo F/25HD 
temperature controller, using the same buffer conditions and oligonucleotide concentrations as for UV 
melting curves. All spectra were recorded at room temperature between 220 to 320 nm, using a 100 
nm/min scan rate. The graphs were analyzed using Origin software. 
 
Luciferase siRNA assays: SH-SY5Y cells were grown at 37 ºC in Dulbecco’s modified Eagle’s 
medium (DMEM; GIBCO) supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin and 
 17
100 µg/mL streptomycin. Cells were regularly passaged to maintain exponential growth. Twenty-four 
hours before transfection at 50–80% confluency, mammalian cells were trypsinized and diluted 1:5 with 
fresh medium without antibiotics (1–3 x 105 cells/mL) and transferred to 24-well plates (500 µL per 
well). Two luciferase plasmids, Renilla luciferase (pRL-TK) and firefly luciferase (pGL3) from Promega, 
were used as a reporter and control, respectively. Cotransfection of plasmids and siRNAs was carried 
out with Lipofectamine 2000 (Life Technologies) as described by the manufacturer for adherent cell 
lines; 1.0 µg pGL3-Control, 0.1 µg pRL-TK and 0.03–26 nM siRNA duplex formulated into liposomes 
were added into each well with a final volume of 600 µL. The cells were harvested 22 h after 
transfection and lysed using passive lysis buffer (100 µL per well) according to the instructions of the 
Dual-Luciferase Reporter Assay System (Promega). The luciferase activities of the samples were 
measured using a MicroLumaPlus LB 96V (Berthold Technologies) with a delay time of 2 s and an 
integrate time of 10 s. The following volumes were used: 20 µL of sample and 30 µL of each reagent 
(Luciferase Assay Reagent II and Stop and Glo Reagent). The inhibitory effects generated by siRNAs 
were expressed as normalized ratios between the activities of the reporter (Renilla) luciferase gene and 
the control (firefly) luciferase gene. 
 
TNF-a siRNA assays: siRNA inhibition experiments with the endogeneous target murine TNF-a were 
performed in RAW 264.7 cells (murine peritoneal macrophages). RAW 264.7 cells were grown at 37 ºC 
in Dulbecco’s modified Eagle’s medium (DMEM; GIBCO) supplemented with 10% fetal bovine serum 
(FBS), 100 U/mL penicillin, 100 µg/mL streptomycin and 10% glutamine. Cells plated a 40-60% 
confluence in 96-well plates were transfected using DOTAP (N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-
trimethylammonium methylsulfate) at an siRNA concentration of 100 nM according to the 
manufacturer’s protocol. Experiments were carried out in triplicate. 20 h after transfection, the cells 
were stimulated with LPS (lipopolysaccharide of gram-negative bacteria) (10 ng/mL) for 10 hours and 
the amount of murine TNF-a produced by the cells (contained in the supernatants from cells) was 
analyzed by enzyme-linked immunoabsorbent assay (ELISA). 
 
Cell stimulation and hTNF-a detection: PBMC cells were obtained from human blood using Ficoll 
density gradient separation.  Enriched monocyte populations were isolated by plastic adherence. After 
three hours incubation at 37ºC, cells were transfected with 10 nM of siRNAs for 18 hours using DOTAP 
(Roche) following the manufacturer’s instructions. Culture supernatants were then collected and hTNF-
α production upon immunostimulation was assessed by ELISA (Bender MedSystems). Experiments 
were carried out in triplicate 
 
Statistical analysis: Data were analyzed by GraphPad Prism 5 program (GraphPad Software). 
Significant differences were assessed by ANOVA to compare three or more groups followed by 
Bonferroni test. In all figures, * represents p values <0.05. 
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Stability assays in 50% human serum: Unmodified or modified double-stranded siRNA samples (20 
µM; 24 µL) were incubated in human serum (24 µL) at 37 ºC. At appropriate periods (0, 0.5, 1, 2, 4, 7 
and 9 hours), 6 µL aliquots of the reaction mixture were added to 54 µL of a 1% sodium dodecyl 
sulphate aqueous solution and the mixtures were heated-denatured for 5 min at 90 ºC. SiRNAs were 
isolated by hot phenol extraction followed by ethanol precipitation. After re-suspension in 20 µL of 
loading buffer (90% formamide, 10% 1X TBE), the samples were run on a denaturing 14% 
polyacrylamide gel containing 20% formamide. RNA bands were visualized with the SYBR Green II 
reagent (Sigma-Aldrich) according to the manufacturer’s instructions. 
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Table S1.  MALDI-TOF mass spectra of synthesized oligonucleotides. 
 
Oligonucleotide Sequence MW calcd. MW 
found 
ss (1) 3'-TTAAAAAGAGGAAGAAGUCUA-5' 6790.0 6787.6 
as (1) 5'-UUUUUCUCCUUCUUCAGAUTT-3' 6423.0 6426.4 
2 5'-TNUUUUCUCCUUCUUCAGAUTT-3' 6429.4 6427.8 
3 5'-pTNUUUUCUCCUUCUUCAGAUTT-3' 6508.0 6513.3 
4 5'- UTNUUUCUCCUUCUUCAGAUTT -3' 6429.5 6440.1 
5 5'- UUUUUCUCCTNUCUUCAGAUTT-3' 6429.5 6435.9 
6 5'- UUUUUCUCCUTNCUUCAGAUTT -3' 6429.5 6437.6 
7 5'- UUUUUCUCCUUCUUCAGAUTNT -3' 6431.3 6437.7 
8 5'- UTNUUUCUCCUUCUUCAGAUTNT -3' 6439.5 6447.3 
9 5'- UTNUTNUCTNCCUUCUUCAGAUTT -3' 6445.9 6456.4 
10 5'- UUUUUCUCCUUCUTNCAGATNTNT -3' 6447.6 6454.3 
11 5'- UTNUTNUCTNCCUUCUTNCAGATNTNT -3' 6472.4 6480.8 
12 5'-UTNTNTNTNCTNCCTNTNCTNTNCAGATNTNT-3' 6513.4 6528.5 
13 5'- UUUUUCUCCUUCUUCAGAUTNTN-3' 6441.4 6442.7 
14 5'-TNTNAAAAAGAGGAAGAAGUCUA-3' 6809.3 6807.4 
16 3'-TTAAAAAGAGGAAGAAGUCTNA-5' 6797.5 6802.7 
17 5'-UUUUUCUCCUUCUUCAGAUTLT-3' 6449.3 6450.1 
18 5'- UTLUTLUCTLCCUUCUTLCAGATLTLT -3' 6435.1 (+Na) 6451.9 
scr-ss (1) 3'-TTAGGAAAGAAAGAAAGCUAU-5' 6790 6796.5 
scr-as (1) 5'-UCCUUUCUUUCUUUCGAUATT-3' 6421.3 6425.4 
scr-10 5'-UCCUUUCTNUUCUUUCGATNATNT-3' 6447.6 6453.2 
scr-16 3'-TTAGGAAAGAAAGAAAGCTNAU-5' 6790.5 (+Na) 6790.3 
20 5'- GAGGCUGAGACAUAGGCACTNT -3' 6782.4 6779.4 
21 3'-TTCUCCGACUCUGUAUCCGUTNG-5' 6567.9 6573.2 
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Figure S1. Separate gene silencing activities for unmodified and modified siRNAs targeting the Renilla 
luciferase mRNA in SH-SY5Y cells. SH-SY5Y cells were transfected with dual reporter plasmids that 
express Renilla luciferase (the target) and nontargeted firefly luciferase as an internal nontargeted 
control and with siRNAs (0.03 nM per well) containing one TN substitution (4, 6 and 7) (A), two and 
three TN substitutions (8, 9 and 10) (B), two TN substitution at the 3'-dinucleotide overhangs (13, 14 and 
15) (C), and with the most active siRNAs (7 and 16) (D), and compared with the unmodified counterpart 
(1). Normalized Renilla luciferase activity is shown. Experiments were carried out in triplicate. Bars 
indicate standard deviation. A Bonferroni test was conducted to evaluate TN modifications to the 
unmodified control (1). In all figures, * indicates a significant change in Renilla luciferase expression 
from unmodified siRNA 1 (p<0.05). 
A                                                                                  B 
  C                                                                                D 
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Figure S2.  Serum stability of unmodified and TN-modified siRNAs. The siRNAs were incubated in 
50% human serum at 37 ºC and withdrawn at indicated time points. The RNAs were separated by 
polyacrylamide gel containing formamide and visualized with SYBR green II. 
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Figure S3.  Sequences of scrambled versions of siRNAs 1, 10 and 16 (scr-1, scr-10 and scr-16) used in 
the RNA interference control experiments. Top strand depicts the sense strand in the 3'–5' direction 
(same as the target sequence). Bottom strand depicts the antisense strand in the 5'–3' direction 
(complementary to the target). TN: North 2’-deoxy MC thymidine monomer 
 
scr-1    3'-TTAGGAAAGAAAGAAAGCUAU-5' 
                 5'-UCCUUUCUUUCUUUCGAUATT-3' 
 
scr-10    3'-TTAGGAAAGAAAGAAAGCUAU-5' 
                 5'-UCCUUUCTNUUCUUUCGATNATNT -3' 
 
scr-16    3'-TTAGGAAAGAAAGAAAGCTNAU-5' 
                   5'-UCCUUUCUUUCUUUCGAUATT-3' 
 
Figure S4.  Plot comparing RNA interference activity of scrambled siRNAs (yellow data, scr-1, scr-10 
and scr-16) to siRNAs 1, 10 and 16 (blue data). Suppression data are for siRNA concentrations of 0.3 
nM. Untreated cells: cells transfected with plasmids alone. 
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Figure S5.  Overlay of CD spectra of siRNAs 1, 5, 8, 9, 11 and 12. Conditions: 1 mM siRNA, 15 mM 
HEPES-KOH (pH 7.4), 1 mM MgCl2 and 50 mM KOAc. 
 
